Global

Recent News Releases

CSL Behring News Releases

CSL Behring Subscribe to alerts

CSL Limited Financial News

25 July 2017
HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Global biotherapeutics leader CSL Behring announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in the United States. More.

21 July 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven years of orphan-drug exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment option for prevention of hereditary angioedema (HAE) attacks. More.

19 July 2017
FDA Accepts CSL Behring’s Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental Biologics License Application (BLA) for Hizentra® [Immune globulin subcutaneous (Human) 20% liquid] for the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. More.

Media Resources

CSL Behring Company Information CSL Behring
Company Information >
CSL Behring Media Contacts CSL Behring
Media Contacts >
CSL Behring Social Media CSL Behring
Social Media >
CSL Behring MultiMedia Library CSL Behring
Images and Videos >



Our Patients' Stories




CSL Behring at a Glance

CSL Behring at a glance







Share
LinkedIn Twitter Facebook Google+